Molecular mechanisms of insulin resistance in obesity and type 2 diabetes mellitus;Molekuláris tényezok szerepe az inzulinrezisztencia- elhízás-2-es típusú diabetes patogenetikai kapcsolatban

Orvosi Hetilap

Volumn 150, Issue 17, 2009, Pages 771-780

  Winkler, Gábor ^a,d   Cseh, Károly ^b,c  

^a ST JOHN'S HOSPITAL   (Hungary)

^b Fovarosi Onkormanyzat Karolyi Sandor Korhaz es Rendelo Intezet   (Hungary)

^c SEMMELWEIS UNIVERSITY   (Hungary)

^d NONE   (Hungary)

Author keywords

Adipocytokines; Insulin receptor; Insulin resistance; Obesity; Signal transduction; Type 2 diabetes mellitus

Indexed keywords

ADIPONECTIN; APELIN; INSULIN RECEPTOR; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PLASMINOGEN ACTIVATOR INHIBITOR; RESISTIN; RETINOL BINDING PROTEIN 4; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

ADIPOSE TISSUE; BRAIN; ENDOTHELIUM CELL; INSULIN RESISTANCE; LIVER; MUSCLE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PANCREAS ISLET BETA CELL; REVIEW; SIGNAL TRANSDUCTION;

ADIPOKINES; ANIMALS; DIABETES MELLITUS, TYPE 2; HUMANS; INSULIN RESISTANCE; LEPTIN; LIPOCALIN 1; MUTATION; OBESITY; PLASMINOGEN INACTIVATORS; RECEPTOR, INSULIN; RESISTIN; RETINOL-BINDING PROTEINS, PLASMA; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 67249111262     PISSN: 00306002     EISSN: 17886120     Source Type: Journal    
DOI: 10.1556/OH.2009.28608     Document Type: Review

References (39)

1. Goldfi ne, I. D., Maddux, B. A., Youngren, J. F. és mtsai: The role of membrane glycoprotein PC-1/ENPP1 in the pathogenesis of insulin resistance and related abnormalities. Endocr. Rev., 2008, 29, 62-75.
2. Winkler G., Cseh K.: Az inzulinrezisztencia zsírszö veti tényezoi. Diabetol. Hung. In press.
3. White, F. M.: Insulin signaling in health and disease. Science, 2003, 302, 1710-1711.
4. Li, C., Zhang, B. B.: Insulin signaling and action: glucose, lipids, protein. http:// www.endotext.org/Diabetes/diabetes4/diabe-tes2.html
5. Ottensmeyer, F. P., Beniac, D. R., Luo, RZ-T. és mtsa: Mechanism of transmembrane signaling: insulin binding and the insulin receptor. Biochemistry, 2000, 39, 12103-12112.
6. Temofonte, N., Sajan, M. P., Nimal, S. és mtsai: Combined thiazolidinedione-metformin treatment synergistically improves insulin signalling to insulin receptor substrate-1-dependent phosphatidylinositol 3-kinase, atypical protein kinase C and protein kinase B/Akt in human diabetic muscle. Diabetologia, 2009, 52, 60-64.
7. Lebrun, P., van Obberghen, E.: SOCS in insulin signaling. Acta Physiol., 2008, 192, 29-36.
8. King, M. W.: AMP activated protein kinase, AMPK. http://themedicalbiochemistrypage.org 2009.
9. Cseh K., Winkler G.: A zsírszöveti "endokrin" szabályozó rendszer és szerepe az inzulinrezisztencia kialakulásában. In Halmos T., Jermendy, Gy. (szerk.): Diabetes mellitus. Elmélet és klinikum. Medicina Kiadó, Budapest, 2002, 98-112.
10. Behre, C. J.: Adiponectin, obesity and atherosclerosis. Scand J. Clin. Lab. Invest., 2007, 67, 449-458.
11. Menzaghi, C., Trischitta, V., Doria, A.: Genetic infl uences of adiponectin on insulin resistance, type 2 diabetes and cardiovascular disease. Diabetes, 2007, 56, 1198-1209.
12. Kadowaki, T., Yamauchi, T., Kubota, N.: The physiological and pathophysiological role of adiponectin and adiponectin receptors in the peripheral tissues and CNS. FEBS Letters, 2008, 582, 74-80.
13. Kubota, N., Yano, W., Kubota, T. és mtsai: Adiponectin stimulates AMP-activated protein kinase in the hypothalamus and increases food intake. Cell Metab., 2007, 6, 55-68.
14. Chehab, F. F.: Obesity and lipodystrophy - Where do the circles intersect? Endocrinology, 2008, 149, 925-934.
15. Myers, M. G.: Leptin receptor signaling and regulation of mammalian physiology. Rec. Progr. Horm. Res., 2004, 59, 287-304.
16. Brennan, A. M., Mantzoros, C. S.: Drug insight: the role of leptin in human physiology and pathophysiology - emerging clinical applications. Nat. Clin. Pract. Endocrinol. Metab., 2006, 2, 318-327.
17. Jiang, L., Jia, Y., Yu, X. és mtsai: Tyrosine-dependent and -independent actions of leptin receptor in control of energy balance and glucose homeostasis. PNAS, 2008, 105, 18619-18624.
18. Kassem, H. S., Arabi, A., Zantout, M. S. és mtsa: Negative effect of leptin on bone mass in type 1 diabetes. Acta Diabetol., 2008, 45, 237-241.
19. Antuna-Puente, B., Fevec, B., Fellahi, S. és mtsa: Adipokines: the missing link between insulin resistance and obesity. Diabetes & Metabolism., 2008, 34, 2-11.
20. Muse, E. D., Lam, T. K., Scherer, P. E. és mtsa: Hypothalamic re-sistin induces hepatic insulin resistance. J. Clin. Invest., 2007, 117, 1670-1678.
21. Goralski, K. B., McCarthy, T. C., Hanniman, E. A. és mtsai: Chemerin, a novel adipokine that regulates adipogenesis and adipocyte metabolism. J. Biol. Chem., 2007, 282, 28175-28188.
22. Bozaoglu, K., Bolton, K., McMillan, J. és mtsai: Chemerin is a novel adipokine associated with obesity and metabolic syndrome. Endocrinology, 2007, 148, 4687-4694.
23. Takahashi, M., Takahashi, Y., Takahashi, K. és mtsai: Chemerin enhances insulin signaling and potentiates insulin-stimulated glucose uptake in 3T3-L1 adipocytes. FEBS Letters, 2008, 582, 573-578.
24. Yang, Q., Graham, T. E., Mody, N. és mtsai: Serum retinol binding protein-4 contributes to insulin resistance in obesity and type 2 diabetes. Nature, 2005, 436, 356-362.
25. Graham, T. E., Yang, Q., Blüher, M. és mtsai: Retinol-binding protein-4 and insulin resistance in lean, obese and diabetic subjects. NEJM, 2006, 354, 2552-2563.
26. Youn, B.-S., Klöting, N., Kratzsch, J. és mtsai: Serum vaspin concentrations in human obesity and type 2 diabetes. Diabetes, 2008, 57, 372-377.
27. Jenkins, A., Zhang, S. X., Gosmanova, A. és mtsai: Increased serum pigment epithelium-derived factor levels in type 2 diabetes. Diab. Res. Clin. Pract., 2008, 82, E5-E7.
28. Ek, E. T. H., Dass, C. R., Choong, P. F. N.: Pigment epithelium-derived factor: a multimodal tumor inhibitor. Mol. Cancer Ther, 2006, 5, 1641-1646.
29. Adeghate, E.: Visfatin, structure, function and relation to diabetes mellitus and other dysfunctions. Curr. Med. Chem., 2008, 15, 1851-1862.
30. Fukuhara, A., Matsuda, M., Nishizawa, M. és mtsai: A protein secreted by visceral fat that mimics the effects of insulin. Science, 2005, 307, 426-430.
31. Song, H. K., Lee, M. H., Kim, B. K. és mtsai: Visfatin: a new player in mesangial cell physiology and diabetic nephropathy. Am. J. Physiol. Renal. Physiol., 2008, 295, F1485-F1494.
32. Gualillo, O., Gonzalez-Juanatey, J. R., Lago, F.: The emerging role of adipokines as mediators of cardiovascular function: physiologic and clinical perspectives. Trend Cardiovasc. Med., 2007, 17, 275-283.
33. Berndt, J., Klöting, N., Kralisch, S. és mtsai: Plasma visfatin concentrations and fat depot-specifi c mRNA expression in humans. Diabetes, 2005, 54, 2911-2916.
34. Wurm, S., Neumeier, M., Weigert, J. és mtsai: Plasma levels of leptin, omentin, collagenous repeat-containing sequence of 26-kDa protein (CORS-26) and adiponectin before and after oral glucose uptake in slim adults. Cardiovasc. Diabetol., 2007, 6, 1-7. (doi: 10.11186/1475-2840-6-7)
35. de Souza Batista, C. M., Yang, R.-Z., Lee, N.-J. és mtsai: Omentin plasma levels and gene expression are decreased in obesity. Diabetes, 2007, 56, 1655-1661.
36. Reaux, A., DeMota, N., Skultetyova, I. és mtsai: Physiological role of a novel neuropeptide, apelin, and its receptor in the rat brain. J. Neurochemistry, 2001, 77, 1085-1096.
37. Tan, B. K., Adya, R., Shan, X. és mtsai: Ex vivo and in vivo regulation of lipocalin-2, a novel adipokine by insulin. Diabetes Care, 2009, 32, 129-131.
38. Li, Y., Dowbenko, D., Lasky, L. A.: Caenorhabditis elegans PIAK, a phospholipid-independent kinase deactivates the Akt-PKB survival kinase. J. Biol. Chem., 2001, 276, 20323-20329.
39. Narbonne, P., Roy, R.: Caenorhabditis elegans dauers need LKB1/AMP to ration lipid reserves and ensure long term survival. Nature, doi:10.1038/nature07536; Published online 3 December 2008.